VENUS REMEDIES
Back to Balance Sheet
|
VENUS REMEDIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹18 Cr | ₹60 Cr | ₹58 Cr | ₹46 Cr | ₹58 Cr |
What is the latest Total Non-Current Liabilities ratio of VENUS REMEDIES ?
Year | Total Non-Current Liabilities |
---|---|
Mar2025 | ₹18 Cr |
Mar2024 | ₹60 Cr |
Mar2023 | ₹58 Cr |
Mar2022 | ₹46 Cr |
Mar2021 | ₹58 Cr |
How is Total Non-Current Liabilities of VENUS REMEDIES Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹18 Cr | -69.12 | |
Mar2024 | ₹60 Cr | 2.89 | |
Mar2023 | ₹58 Cr | 26.60 | |
Mar2022 | ₹46 Cr | -20.94 | |
Mar2021 | ₹58 Cr | - |
Compare Total Non-Current Liabilities of peers of VENUS REMEDIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
VENUS REMEDIES | ₹632.5 Cr | -3.5% | -10% | 22.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹394,115.0 Cr | 3.5% | -3.4% | -5.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹162,735.0 Cr | 3.7% | -10.2% | 25.6% | Stock Analytics | |
CIPLA | ₹126,313.0 Cr | 5.3% | 6.1% | -1.3% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹122,592.0 Cr | 1.4% | 4.6% | 7.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,095.0 Cr | 3.9% | 0% | -9.9% | Stock Analytics |
VENUS REMEDIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VENUS REMEDIES | -3.5% |
-10% |
22.3% |
SENSEX | -0% |
-2.4% |
1.2% |
You may also like the below Video Courses